CVS Health (CVS) Guidance summary
Event summary combining transcript, slides, and related documents.
Guidance summary
4 Nov, 2026Opening remarks and agenda
FY18 outlook issued ahead of the February earnings call; remarks focused on operating and segment performance, with no incremental information on the pending Aetna acquisition.
Guidance on key objectives
FY18 consolidated revenue growth of 0.75%–2.5% and adjusted operating profit growth of 1%–4%; adjusted EPS guidance was omitted because below-the-line timing made the range too wide.
FY18 Retail/LTC revenue growth of 2.5%–4%, same-store sales growth of 2%–3.5%, and same-store script growth of 6%–7%; adjusted operating profit growth in the low single digits.
FY18 Pharmacy Services revenue growth of 1.5%–3.5%, adjusted claims of 1.91B–1.93B (~8% growth), and operating profit growth in the low-to-mid single digits.
FY18 net interest expense of $2.0B–$2.3B and tax rate of ~27%; tax reform expected to add ~$1.2B to annual net income and cash flow.
FY17 consolidated adjusted operating profit growth and adjusted EPS expected at the lower ends of 5.75%–8% and $1.88–$1.92 ranges; Pharmacy Services growth expected at ~4%.
Market trends and strategic opportunities
Retail/LTC script growth supported by Optum, Cigna and Express Scripts partnerships, broader Medicare Part D preferred-pharmacy participation, LTC initiatives and purchasing efficiencies.
Pharmacy Services growth drivers include higher network and specialty volumes, Medicare Part D lives, Red Oak purchasing efficiencies and Aetna Medicare Part D rebate administration; generic introductions and lower brand inflation affect revenue.
PBM revenue and margins face pricing pressure; clients showed interest in value-based contracts and service models linking outcomes, while Maintenance Choice and performance-based networks offered growth opportunities.
Latest events from CVS Health
- Separation aims to unlock standalone growth while preserving investment-grade balance sheets.CVS
8th Annual Wolfe Research Healthcare Conference - Care delivery expansion and post-deleveraging capital choices shape the forward strategy.CVS
30th Annual Credit Suisse Healthcare Conference - PBM cost controls, health plan growth and integrated care underpin the outlook.CVS
The 2016 Morgan Stanley Global Healthcare Conference - Integrated pharmacy scale supported growth and more than $5B in planned 2016 shareholder returns.CVS
The UBS 2016 Global Healthcare Conference - Integrated pharmacy and clinical programs aim to improve outcomes and reduce care costs.CVS
UBS Global Healthcare Conference 2017 - Signify bolsters in-home care and value-based strategy amid stable utilization.CVS
Morgan Stanley 20th Annual Global Healthcare Conference - Aetna integration targets >$750M in 2020 synergies and broader medical-cost savings.CVS
JP Morgan 37th Annual Healthcare conference - Cost savings and payer partnerships support long-term growth and shareholder returns.CVS
Investor Day 2016 - A $77B Aetna deal targets integrated care and $750M in year-two synergies.CVS
M&A announcement